Search

Your search keyword '"Calandrino, R."' showing total 722 results
Start Over Author "Calandrino, R."
722 results on '"Calandrino, R."'

51. EP-1319: “Adjuvant”/ radical radiotherapy in prostate cancer patients with synchronous bone oligometastasis

Author

Deantoni, C.L., primary, Fodor, A., additional, Sini, C., additional, Noris Chiorda, B., additional, Cozzarini, C., additional, Fiorino, C., additional, Dell'Oca, I., additional, Picchio, M., additional, Incerti, E., additional, Mangili, P., additional, Calandrino, R., additional, Gianolli, L., additional, and Di Muzio, N., additional

Published
2017
Full Text
View/download PDF

52. EP-1318: Is hypofractionation combined to WPRT effective in high risk prostate cancer patients?

Author

Di Muzio, N.G., primary, Fodor, A., additional, Deantoni, C.L., additional, Noris Chiorda, B., additional, Broggi, S., additional, Mangili, P., additional, Dell'Oca, I., additional, Chiara, A., additional, Passoni, P., additional, Slim, N., additional, Pasetti, M., additional, Calandrino, R., additional, Cozzarini, C., additional, and Fiorino, C., additional

Published
2017
Full Text
View/download PDF

54. Multidetector computed tomography for coronary stents imaging: high-voltage (140-kVp) prospective ECG-triggered versus standard-voltage (120-kVp) retrospective ECG-gated helical scanning

Author

ESPOSITO, ANTONIO, DE COBELLI, FRANCESCO, DEL MASCHIO, ALESSANDRO, Colantoni, C, Del Vecchio, A, Palmisano, A, Calandrino, R, PALMISANO , ANNA, Esposito, Antonio, Colantoni, C, DE COBELLI, Francesco, Del Vecchio, A, Palmisano, A, Calandrino, R, and DEL MASCHIO, Alessandro

Subjects
Male, medicine.medical_treatment, Cardiac-Gated Imaging Techniques, Coronary Disease, Coronary Angiography, Radiation Dosage, Effective dose (radiation), Statistics, Nonparametric, Electrocardiography, Multidetector Computed Tomography, medicine, Humans, Radiology, Nuclear Medicine and imaging, cardiovascular diseases, Prospective Studies, Prospective cohort study, Cardiac imaging, Aged, Retrospective Studies, medicine.diagnostic_test, business.industry, Helical scan, Stent, Middle Aged, Coronary arteries, medicine.anatomical_structure, Angiography, Radiographic Image Interpretation, Computer-Assisted, Female, Stents, Nuclear medicine, business
Abstract

OBJECTIVE To compare prospective electrocardiogram (ECG)-triggered high-voltage coronary computed tomography (CT) angiography (CTA; 140-kVp P-cCTA) with retrospective ECG-gated standard-voltage cCTA (120-kVp R-cCTA), in patients with coronary stents. METHODS Fifty-two patients with coronary stents were studied with 64-slice multidetector scanner. Ninety-three stents were analyzed: 55 with 140-kVp P-cCTA and 38 with 120-kVp R-cCTA. Image quality (IQ), diagnostic confidence (DC), in-stent assessable lumen, artificial narrowing, and effective radiation dose were compared between techniques. RESULTS Image quality and DC were significantly better for the 140-kVp P-cCTA in comparison with the 120-kVp R-cCTA (IQ, 1.1 ± 0.36 vs 1.7 ± 0.60, respectively; P < 0.00001. Diagnostic confidence: 1.1 ± 0.29 vs 1.5 ± 0.65 respectively; P < 0.0001). In-stent assessable lumen and artificial narrowing were comparable between the techniques. Effective dose was lower for the 140-kVp P-cCTA (6.7 ± 2.07 mSv vs 15.8 ± 6.89 mSv; P < 0.0001). CONCLUSIONS High voltage combined with axial prospective ECG-triggered scan improved IQ and DC in stent cCTA imaging but failed to improve the diameter of in-stent assessable lumen and to reduce the artificial narrowing compared with the 120-kVp R-cCTA. Effective dose was 60% lower for the 140-kVp P-cCTA.

Published
2013

55. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study

Author

Passoni P, Reni M, Cattaneo GM, Slim N, Cereda S, Balzano G, Castoldi R, Longobardi B, Bettinardi V, Gianolli L, Gusmini S, Staudacher C, Calandrino R, Di Muzio N, Passoni, P, Reni, M, Cattaneo, Gm, Slim, N, Cereda, S, Balzano, G, Castoldi, R, Longobardi, B, Bettinardi, V, Gianolli, L, Gusmini, S, Staudacher, C, Calandrino, R, and Di Muzio, N

Published
2013

57. Biological optimization of simultaneous boost on intra-prostatic lesions (DILs): sensitivity to TCP parameters

Author

Azzeroni R, Maggio A, Fiorino C, Mangili P, Cozzarini C, Di Muzio Ng, Calandrino R., DI MUZIO, NADIA GISELLA, DE COBELLI , FRANCESCO, Azzeroni, R, Maggio, A, Fiorino, C, Mangili, P, Cozzarini, C, DE COBELLI, Francesco, Di Muzio, Ng, Calandrino, R., and DI MUZIO, NADIA GISELLA

Subjects
Simultaneous integrated boost, Male, business.industry, Minimum distance, Statistics as Topic, Biophysics, Uncertainty, General Physics and Astronomy, Prostatic Neoplasms, Radiobiology, Radiotherapy Dosage, General Medicine, Radiotherapy, Computer-Assisted, Dose escalation, Biological optimization, Prostate radiotherapy, Humans, Radiology, Nuclear Medicine and imaging, Sensitivity (control systems), Nuclear medicine, business, Mathematics, Biomedical engineering, Probability
Abstract

The aim of this investigation was to explore the potential of biological optimization in the case of simultaneous integrated boost on intra-prostatic dominant lesions (DIL) and evaluating the impact of TCP parameters uncertainty. Different combination of TCP parameters (TD50 and γ50 in the Poisson-like model), were considered for DILs and the prostate outside DILs (CTV) for 7 intermediate/high-risk prostate patients. The aim was to maximize TCP while constraining NTCPs below 5% for all organs at risk. TCP values were highly depending on the parameters used and ranged between 38.4% and 99.9%; the optimized median physical doses were in the range 94–116 Gy and 69–77 Gy for DIL and CTV respectively. TCP values were correlated with the overlap PTV-rectum and the minimum distance between rectum and DIL. In conclusion, biological optimization for selective dose escalation is feasible and suggests prescribed dose around 90–120 Gy to the DILs. The obtained result is critically depending on the assumptions concerning the higher radioresistence in the DILs. In case of very resistant clonogens into the DIL, it may be difficult to maximize TCP to acceptable levels without violating NTCP constraints.

Published
2012

59. Feasibility of safe ultra-high (EQD(2)>100 Gy) dose escalation on dominant intra-prostatic lesions (DILs) by Helical Tomotheraphy

Author

Maggio A, Fiorino C, Mangili P, Cozzarini C, Cattaneo Gm, Rancati T, Maschio Ad, Muzio Nd, Calandrino R., DE COBELLI , FRANCESCO, Maggio, A, Fiorino, C, Mangili, P, Cozzarini, C, DE COBELLI, Francesco, Cattaneo, Gm, Rancati, T, Maschio, Ad, Muzio, Nd, and Calandrino, R.

Abstract

PURPOSE: to verify the possibility of using Helical Tomotherapy to safely escalate dose to single or multiple highly radioresistant dominant intra-prostatic lesions (DILs) as assessed by functional magnetic resonance imaging (MRI). MATERIAL: in seven intermediate/high risk patients, T2WI, T1WI and DWI MRI imaging showed evidence of one DIL in four patients and two DILs in three patients in the peripheral zone of the prostate. The planning strategy was to deliver median doses of 80, 90, 100 and 120 Gy to PTVDIL while delivering 71.4 Gy/28 fractions (EQD(2)=75 Gy) to the remaining portion of PTV. A higher priority was assigned to rectal constraints relative to DIL coverage. Rectal NTCP calculations were performed using the most recently available model data. RESULTS: the median dose to DIL could safely be escalated to at least 100 Gy (EQD(2,α/β=10)=113 Gy) without violating safe constraints for the organs at risk. Typical rectal NTCP values were around or below 1-3% for G3 toxicity and 5-7% for G2-G3 toxicity. For the 100 Gy DIL dose boost strategy, mean D95% of DIL and PTVDIL were 98.8 Gy and 86.7 Gy, respectively. The constraints for bladder, urethra and femoral heads were always respected. CONCLUSIONS: IGRT by Helical Tomotherapy may permit the safe escalation of EQD(2,α/β=10) to at least 113 Gy to DILs without significantly increasing rectal NTCP compared to plans without dose escalation. A Phase I-II clinical study is warranted

Published
2011

61. Helical tomotherapy vs. intensity-modulated proton therapy for whole pelvis irradiation in high-risk prostate cancer patients: dosimetric, normal tissue complication probability, and generalized equivalent uniform dose analysis

Author

Widesott L, Pierelli A, Fiorino C, Lomax AJ, Amichetti M, Cozzarini C, Soukup M, Schneider R, Hug E, Di Muzio N, Calandrino R, Schwarz M, Widesott, L, Pierelli, A, Fiorino, C, Lomax, Aj, Amichetti, M, Cozzarini, C, Soukup, M, Schneider, R, Hug, E, Di Muzio, N, Calandrino, R, and Schwarz, M

Published
2011

63. Tomoterapia ed ipofrazionamento

Author

Di Muzio, N, Schipani, S, Cozzarini, C, Passoni, P, LANDONI, CLAUDIO, Bettinardi, V, Danna, M, Cattaneo, M, Fiorino, C, Calandrino, R, FAZIO, FERRUCCIO, Di Muzio, N, Schipani, S, Cozzarini, C, Passoni, P, Landoni, C, Bettinardi, V, Danna, M, Cattaneo, M, Fiorino, C, Calandrino, R, and Fazio, F

Subjects
MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA, Medicine (all), Hypofractionation, Tomotherapy, Cancer
Abstract

Current imaging methods permit an accurate target definition in radiotherapy considered as a fundamental requirement for precise treatment execution. The combination of PET/CT and tomotherapy has as its objective the early, accurate recognition of tumor extension (staging), optimal definition of treatment volume and complete response of the treated lesion, providing a valid alternative to surgery not only in advanced disease but also in potential surgical cases. This new technical approach has resulted in a previously unreachable level of selectivity in radiation therapy, together with more reliable target definition, better control of target position, improved patient set up reproducibility and dramatically dose fall-off between tumor and surrounding normal tissues. The clinical result consists not only in the possibility to deliver significantly higher dose but also the realization of hypofractionated treatments. Metabolically guided radiotherapy and hypofractionation can result in a series of advantages: improvement in treatment quality (set-up error reduction, effective dose fall-off and control of target movement); elevated disease control for the possibility of higher dose radiation and reduced side effects; greater frequency of complete clinical response with possibility of avoiding surgery; improved patient management (in terms of logistic and economic problems); more patients treated per machine with significant reduction of waiting list (the time factor from radiobiological perspective is an important variable to disease control); cost containment (by means of hypofractionation it is possible to reduce the number of treatment and consequently the total cost of therapy). To this end both methodological and clinical protocols have been drown up at our Institution (Hospital San Raffaele: HSR) and approved by the Ethics Committee. The clinical protocols are relative to treatment of pulmonary neoplasm, prostate cancer, head and neck cancer, pancreatic cancer, lung and liver lesions. In this paper the following issues will be considered: prostate cancer (radical and adjuvant treatment), liver and lung lesions and locally advanced pancreatic cancer. Copyright © 2007 by new Magazine edizioni s.r.l.

Published
2007

71. EP-1300: Preoperative, Adaptive Radiotherapy with Tomotherapy concomitant with chemotherapy in rectal cancer

Author

Passoni, P., primary, Slim, N., additional, Fiorino, C., additional, Gumina, C., additional, Ronzoni, M., additional, De Cobelli, F., additional, Palmisano, A., additional, Ricci, V., additional, Fasolo, A., additional, Tamburini, A., additional, De Nardi, P., additional, Di Palo, S., additional, Staudacher, C., additional, Rosati, R., additional, Calandrino, R., additional, and Di Muzio, N., additional

Published
2016
Full Text
View/download PDF

73. EP-2053: In-vivo imaging of rat leukocytes redistribution after pelvic irradiation

Author

Benigni, F., primary, Cozzarini, C., additional, Sini, C., additional, Spinelli, A., additional, Venturini, M., additional, Perani, L., additional, Sacco, V., additional, Viale, A., additional, Capelli, A., additional, Mondino, A., additional, Briganti, A., additional, Bellone, M., additional, Fiorino, C., additional, Calandrino, R., additional, and Di Muzio, N., additional

Published
2016
Full Text
View/download PDF

76. EP-1079: Clinical outcomes in locally advanced oropharyngeal cancer 18FDG PET-guided dose escalation IMRT-SIB

Author

Chiara, A., primary, Fiorino, C., additional, Picchio, M., additional, Fodor, A., additional, Broggi, S., additional, Pasetti, M., additional, Incerti, E., additional, Mapelli, P., additional, Zerbetto, F., additional, De Antoni, C., additional, Azizi, M., additional, Calandrino, R., additional, Dell'Oca, I., additional, and Di Muzio, N., additional

Published
2016
Full Text
View/download PDF

80. PO-0870: Fitting data of relapse-free survival after postprostatectomy RT with a comprehensive TCP model

Author

Fiorino, C., primary, Broggi, S., additional, Fossati, N., additional, Cozzarini, C., additional, Goldner, G., additional, Wiegel, T., additional, Hinkelbein, W., additional, Karnes, J.R., additional, Boorjian, S.A., additional, Haustermans, K., additional, Joniau, S., additional, Shariat, S., additional, Montorsi, F., additional, Van Poppel, H., additional, Di Muzio, N.G., additional, Calandrino, R., additional, and Briganti, A., additional

Published
2016
Full Text
View/download PDF

81. EP-1349: Long term results of a phase I-II study of moderate hypofractionated IGRT in prostate cancer

Author

Di Muzio, N., primary, Fodor, A., additional, Noris Chiorda, B., additional, Broggi, S., additional, Mangili, P., additional, Valdagni, R., additional, Dell'Oca, I., additional, Pasetti, M., additional, Deantoni, C., additional, Chiara, A., additional, Berardi, G., additional, Briganti, A., additional, Calandrino, R., additional, Cozzarini, C., additional, and Fiorino, C., additional

Published
2016
Full Text
View/download PDF

83. 552 Predicting the 5-year risk of biochemical relapse after post-prostatectomy radiotherapy in ≥pT2 patients with a comprehensive radiobiological model

Author

Fiorino, C., primary, Broggi, S., additional, Fossati, N., additional, Cozzarini, C., additional, Goldner, G., additional, Wiegel, T., additional, Hinkelbein, W., additional, Karnes, J., additional, Haustermans, K., additional, Joniau, S., additional, De Ridder, D., additional, Shariat, S., additional, Montorsi, F., additional, Van Poppel, H., additional, Di Muzio, N., additional, Calandrino, R., additional, and Briganti, A., additional

Published
2016
Full Text
View/download PDF

85. 61 Prophylactic irradiation of pelvic lymph-nodal area after prostatectomy does not increase the risk of second neoplasms: A single institution analysis of 1109 patients with 10 years follow-up

Author

Sini, C., primary, Cozzarini, C., additional, Fiorino, C., additional, Briganti, A., additional, Deantoni, C., additional, Fodor, A., additional, Fossati, N., additional, Gandaglia, G., additional, Noris Chiorda, B., additional, Perna, L., additional, Montorsi, F., additional, Calandrino, R., additional, and Di Muzio, N., additional

Published
2016
Full Text
View/download PDF

86. 553 Salvage tomotherapy choline PET/CT guided for prostate cancer lymph nodal recurrence

Author

Fodor, A., primary, Genoveffa, B., additional, Fiorino, C., additional, Picchio, M., additional, Busnardo, E., additional, Kirienko, M., additional, Incerti, E., additional, Cozzarini, C., additional, Dell'Oca, I., additional, Mangili, P., additional, Pasetti, M., additional, Calandrino, R., additional, Gianolli, L., additional, and Di Muzio, N.G., additional

Published
2016
Full Text
View/download PDF

98. Predicting Clinical Outcome Following Post Prostatectomy Radiation Therapy: A Poisson-Based Tumor Control Probability (TCP) Model Based on a Large Multi-institutional Series

Author

Fiorino, C., primary, Broggi, S., additional, Fossati, N., additional, Cozzarini, C., additional, Goldner, G., additional, Wiegel, T., additional, Hinkelbein, W., additional, Karnes, J.R., additional, Haustermans, K., additional, Joniau, S., additional, Shariat, S., additional, Montorsi, F., additional, Van Poppel, H., additional, Di Muzio, N.G., additional, Calandrino, R., additional, and Briganti, A., additional

Published
2015
Full Text
View/download PDF

99. Optical imaging of radioisotopes: a novel multimodal approach to molecular imaging

Author

Antonello Enrico Spinelli, Marengo, M., Calandrino, R., Sbarbati, A., and Boschi, F.

Subjects
Radioisotopes, radiotracers imaging, Cerenkov radiation, planar Cerenkov luminescence imaging, optical imaging in vivo, Optical Phenomena, Luminescent Measurements, Animals, Humans, Molecular Imaging
Abstract

In this review there will be presented an overview of the literature about the recent developments on radiotracers imaging using optical methods and their applications. We will begin with a short summary regarding the discovery of Cerenkov radiation (CR) and then focus on the early developments and experimental validation of planar Cerenkov luminescence imaging. A significant improvement in Cerenkov luminescence imaging was given by the development of tomographic methods in order to obtain in vivo whole body 3D images of Cerenkov sources. An interesting and original application discussed in this review is the use of CR as the excitation source of quantum dots and fluorophores. We will also present some recent experimental results on in vivo radio luminescence imaging of alpha and gamma emitters. All these results make optical radioisotopes imaging an interesting cost-effective tool for the screening of new probes for both imaging and therapeutic applications. Other interesting aspects are the uses of Cerenkov radiation for radiotherapy and for radiopharmaceuticals synthesis applications. We will conclude by summarising the most important results and the future challenges.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results